dc.date.accessioned | 2022-02-04T19:34:52Z | |
dc.date.available | 2022-02-04T19:34:52Z | |
dc.date.created | 2021-11-19T13:46:57Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Tunheim, Gro Rø, Gunnar Øyvind Isaksson Tran, Trung Kran, Anne-Marte Bakken Andersen, Jan Terje Vaage, Eline Benno Kolderup, Anette Vaage, John T. Lund-Johansen, Fridtjof Hungnes, Olav . Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic. Influenza and Other Respiratory Viruses. 2021, 1-9 | |
dc.identifier.uri | http://hdl.handle.net/10852/90538 | |
dc.description.abstract | Background
Infection with the novel coronavirus SARS-CoV-2 induces antibodies that can be used as a proxy for COVID-19. We present a repeated nationwide cross-sectional study assessing the seroprevalence of SARS-CoV-2, the infection fatality rate (IFR), and infection hospitalization rate (IHR) during the first year of the pandemic in Norway.
Methods
Residual serum samples were solicited in April/May 2020 (Round 1), in July/August 2020 (Round 2) and in January 2021 (Round 3). Antibodies against SARS-CoV-2 were measured using a flow cytometer-based assay. Aggregate data on confirmed cases, COVID-19-associated deaths and hospitalizations were obtained from the Emergency preparedness registry for COVID-19 (Beredt C19), and the seroprevalence estimates were used to estimate IFR and IHR.
Results
Antibodies against SARS-CoV-2 were measured in 4840 samples. The estimated seroprevalence increased from 0.8% (95% credible interval [CrI] 0.4%–1.3%) after the first wave of the pandemic (Rounds 1 and 2 combined) to 3.2% (95% CrI 2.3%–4.2%) (Round 3). The IFR and IHR were higher in the first wave than in the second wave and increased with age. The IFR was 0.2% (95% CrI 0.1%–0.3%), and IHR was 0.9% (95% CrI 0.6%–1.5%) for the second wave.
Conclusions
The seroprevalence estimates show a cumulative increase of SARS-CoV-2 infections over time in the Norwegian population and suggest some under-recording of confirmed cases. The IFR and IHR were low, corresponding to the relatively low number of COVID-19-associated deaths and hospitalizations in Norway. Most of the Norwegian population was still susceptible to SARS-CoV-2 infection after the first year of the pandemic. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic | |
dc.type | Journal article | |
dc.creator.author | Tunheim, Gro | |
dc.creator.author | Rø, Gunnar Øyvind Isaksson | |
dc.creator.author | Tran, Trung | |
dc.creator.author | Kran, Anne-Marte Bakken | |
dc.creator.author | Andersen, Jan Terje | |
dc.creator.author | Vaage, Eline Benno | |
dc.creator.author | Kolderup, Anette | |
dc.creator.author | Vaage, John T. | |
dc.creator.author | Lund-Johansen, Fridtjof | |
dc.creator.author | Hungnes, Olav | |
cristin.unitcode | 185,53,49,12 | |
cristin.unitname | Institutt for kreftforskning | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1956496 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Influenza and Other Respiratory Viruses&rft.volume=&rft.spage=1&rft.date=2021 | |
dc.identifier.jtitle | Influenza and Other Respiratory Viruses | |
dc.identifier.startpage | 1 | |
dc.identifier.endpage | 9 | |
dc.identifier.doi | https://doi.org/10.1111/irv.12932 | |
dc.identifier.urn | URN:NBN:no-93112 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1750-2640 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/90538/1/Tunheim_2021_Tre.pdf | |
dc.type.version | PublishedVersion | |